HEALTH TECHNOLOGY

Vuzix Corporation Collaborates with Hippo Technologies, Inc., to Connect Global Healthcare and Medical Networks

Vuzix | January 21, 2021

Vuzix Corporation a leading provider of Smart Glasses and Augmented Reality innovation and items, today declared it is working together with Hippo Technologies, Inc., a virtual consideration organization conveying answers for healthcare and clinical instruction, to interface worldwide specialists and healthcare suppliers with essential clinical organizations and virtual consideration administrations with Vuzix M400 and M4000 Smart Glasses.

Hippo Virtual CareTM is an interoperable stage interfacing endeavor frameworks, data sets, IOT gadgets, wearables and technologies together to overcome any issues between actual consideration and virtual consideration. Its item arrangements incorporate without hands, voice-actuated Vuzix Smart Glasses and other head-worn gadgets alongside HIPAA and GDPR agreeable programming that permits clinicians to convey and videoconference continuously. Far off partners and understudies can look through clinical records, and consequently access documents and imaging during quiet assessments, methodology, counsels and adjusting. Hippo Virtual Care improves clinical productivity, empowering quicker emergency, more astute clinical dynamic, and upgraded commitment with patients.

"Hippo Virtual Care unlocks a new paradigm of mobile computing – using hands-free and voice-centric smart glasses offerings that fit the evolution taking place in healthcare and deliver on the promise of virtual care regardless of distance, time and training," commented Brian Hamilton, President and co-founder of Hippo Technologies, Inc. "We look forward to the continued collaboration and partnership with Vuzix."

"We are very pleased to expand our partner's healthcare solutions portfolio and welcome Hippo Technologies, Inc., as a Vuzix Smart Glasses platform partner to support their network of healthcare professionals to deliver medical and surgical services through the use of Vuzix Smart Glasses," said Paul Travers, President and CEO of Vuzix. 

About Hippo Technologies, Inc.

Hippo Technologies, Inc., is a virtual care company delivering products and services for healthcare and medical education. Its Hippo Virtual CareTM platform is interoperable connecting enterprise systems, databases, IOT devices, wearables and technologies together to bridge the gap between physical care and virtual care. Its products include hands-free, voice-activated, head-worn devices and HIPAA and GDPR compliant software allowing clinicians to communicate and collaborate virtually in real time with remote colleagues and students, search medical records, and automatically access files and imaging during patient examinations, procedures, consultations and rounding. Hippo delivers a unique "through the eyes of the clinician" experience with all the safety and convenience of remote care.

About Vuzix Corporation

Vuzix is a leading supplier of Smart-Glasses and Augmented Reality (AR) technologies and products for the consumer and enterprise markets. The Company's products include personal display and wearable computing devices that offer users a portable high-quality viewing experience, provide solutions for mobility, wearable displays and augmented reality. Vuzix holds 179 patents and patents pending and numerous IP licenses in the Video Eyewear field. The Company has won Consumer Electronics Show (or CES) awards for innovation for the years 2005 to 2021 and several wireless technology innovation awards among others. Founded in 1997, Vuzix is a public company (NASDAQ: VUZI) with offices in Rochester, NY, Oxford, UK, and Tokyo, Japan.

Spotlight

Simplee commissioned Forrester Consulting to conduct a Total Economic Impact TEI study and examine the potential return on investment ROI enterprises may realize by deploying Simplee’s platform for patient financial care. The purpose of this study is to provide readers with a framework to evaluate the potential financial impact of Simplee on their organizations.


Other News
FUTURE OF HEALTHCARE

Winner Medical Acquires Majority Stake in Pingan Medical to Fuel Growth

Winner Medical | June 02, 2022

Winner Medical Co. Ltd. a leading manufacturer of disposable wound care and surgical products, announced on May 18 that it will acquire a majority 65.55% stake in Hunan Pingan Medical Device Technology Co. Ltd. for 652 million yuan as the Company continues to expand its disposable medical supply lineup. Upon the completion of the deal, Winner Medical is set to hold a total of 68.7% stake in Pingan Medical for a total of 752 million yuan. The Company's move comes as it looks to make a foray into the field of injection products to diversify its product offerings besides consumer products, and comes in line with its strategy to provide one-stop disposable medical supply solutions. Established in 2010, Pingan Medical mainly produces disposable medical devices, such as syringes, infusion sets, and blood collection tubes among other medical supplies. In 2021, Pingan Medical recorded 360 million yuan in revenue and booked a net profit of 85 million yuan. The acquisition will leverage both companies' strengths and help fill the product gap in injection-related disposables of Winner Medical, enabling it to expand into new medical verticals and achieve its goal of becoming a major supplier for the domestic market. Specifically, the Company plans to roll out medical sets that comprise needle-type products from Pingan Medical and wound care supplies from Winner Medical, providing one-stop customized solutions for hospitals and large medical centers. Meanwhile, Winner Medical will help Pingan Medical with its industry-leading R&D capabilities to develop medical device solutions and build smart manufacturing plants. To fuel the growth based on the new deal, Winner Medical has signed an investment note with the local government of Li County in Hunan Province, where Pingan Medical is headquartered, to build medical equipment production lines, smart warehousing, and R&D facilities. The latest deal follows Winner Medical's April-11 acquisition of wound dressing maker Zhejiang Longterm Medical Technology Co. Ltd. as part of its expansion strategy to stay competitive in the area of high-end wound dressings. The Company has also set up a dedicated team to promote its self-developed wound dressing products as the market for such medical supplies is still in its infancy in China. Founded in 1991, Winner Medical has made efforts to offer quality cotton-based medical dressings and disposables, and will continue to push ahead with its strategy to diversify its product lineup and boost consumption. On the manufacturing front, the Company aims to expand to new medical verticals through acquisitions, while on the consumption front, it plans to enhance product sales through digitization and gradually phasing out less popular products. As such, the Company has made significant progress in digitizing its operations. Winner Medical has gone live on multiple e-commerce platforms, and has gone digital in terms of online and offline warehousing and order management.

Read More

FUTURE OF HEALTHCARE

OmniLife Partners With Redox to Add Patient Referral Management Tool to Its End-to-End Communication Platform for Transplant Hospitals.

OmniLife | March 25, 2022

OmniLife, a health technology communication and collaboration platform, has partnered with Redox, the industry-leading electronic health record integration and healthcare interoperability platform, to create a new integrated patient management tool as part of its overarching platform that provides end-to-end communication solutions for transplant hospitals. The new patient modules, OmniReferral and PatientStatus, will allow transplant centers to easily review new referrals and share updates on patient status to providers and allows transplant centers to customize their own digital forms to make it easier for providers to refer and then monitor the activity and status of transplant patients. The tool also integrates into the EHR patient checklists and allows centers using EHRs to easily share patient status updates with referring providers. OmniReferral and PatientStatus is built to be organ agnostic, allowing centers to use the tool across all organ departments and with any referring provider. OmniLife has been leading efforts to improve communication, decision making, and secure information exchange between all stakeholders in the greater allotransplant ecosystem. Additionally, OmniLife is currently participating in a clinical trial funded by the National Institutes of Health (NIH) for a Small Business Innovation Research (SBIR) which includes notable centers such as UPMC Children’s Hospital of Pittsburgh, Loma Linda University Transplant Institute, and Stanford Health Care Transplant Program. About OmniLife OmniLife is a certified Benefit Corporation focused on maximizing the gift of life for purposes of transplantation and research. OmniLife is the only end-to-end communication and clinical workflow software platform that is built specifically to create a more connected and collaborative allotransplant ecosystem.

Read More

DIGITAL HEALTHCARE

MedX Health and Health Partners Announce Agreement to Launch MedX’s Teledermatology Screening Platform

MedX Health Corp | March 03, 2022

MedX Health Corp.("MedX" or the "Company"), a global leader in teledermatology, is pleased to announce a Memorandum of Understanding (“MOU”) and the launch of a new commercialization pilot project with Health Partners (OH) Limited, a well-respected, privately-owned corporate health, treatment and primary care services company in the United Kingdom. Serving a broad client base comprising corporates, government agencies, insurers, health trusts, pension funds and individuals, Health Partners (“HP”) employs 700+ people with telehealth, mobile and on-site operations across the UK and the Republic of Ireland. The pilot will span three to six months and involve an estimated 600 patients across two of HP’s sites. Upon the successful completion of the pilot, the MedX DermSecure® Screening Platform will be made available to Health Partners' two million-plus patients. The agreement is the latest initiative in MedX’s global commercialization strategy and follows pilots recently launched across the Europe and Middle East region. "Health Partners’ Clinical Team constantly strives to identify leading technological innovations that offer the highest level of support to our two million-plus patients. MedX's leading skin assessment technology allows dermatologists to not only make more accurate diagnoses of pigmented lesions and moles, but to do that remotely and quickly. We are very proud to be partnering with MedX Health to bring this innovative and life-changing service to our clients.” Health Partners Managing Director Andrew Noble In addition to expanding its DermSecure® Screening Platform network globally, MedX has focused on building a presence in multiple market verticals such as pharmacies, medical clinics, building hubs, medical scanning clinics, mobile and remote medical practices, as well as esthetics and skincare clinics. The partnership with Health Partners represents MedX’s expansion into a new vertical; occupational health and wellbeing services. MedX Managing Director, Europe, Middle East and Africa (EMEA), Naman Demaghlatrous, added, "MedX is pleased to have established a presence in the strategic occupational health vertical. Health Partners brings our technology to a population of more than two million workers across the United Kingdom, thus expanding our footprint in the EMEA region considerably. We continue to execute on our strategy to identify strategic partnerships in the region that will allow us to grow our business and save lives simultaneously.” Health Partners will pilot MedX’s high-definition image-capture technology, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®, which transmits and stores patient data throughout the assessment process. MedX's SIAscopy® is the only technology available that captures five high-resolution images of suspicious moles, lesions and skin conditions, including four spectrophotometric images taken 2mm below the skin's surface. This technology provides detailed patient scans, which a certified dermatologist can virtually assess within 72 hours. "We are honoured to be working with Health Partners on this most important initiative. According to Health & Safety Executive-commissioned research, there are more than 3000 cases of skin cancer annually in the construction industryalone. We are delighted to be entering the occupational health services market with a leader in the industry," stated Mike Druhan, MedX President, Dermatology Services. About Health Partners (OH) Ltd. Health Partners, headquartered in Uckfield, East Sussex, United Kingdom, is a leading health and wellbeing company, providing a full range of corporate health, treatment and primary care services to corporates, government, insurers, health trusts, pension funds and families. We combine expert advice and clinical services with smart systems to deliver impact-driven health programmes, tailored to improve people’s wellbeing and performance. Health Partners is founded on patient privacy and holds a significant number of accreditations, certifications and memberships, including ISO27001, CQC, SEQOHS and ISO9001. Health Partners offers its services across the United Kingdom and the Republic of Ireland, reaching two million plus people in organisations across several industries. About MedX Health Corp. MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view suspicious moles and lesions up to 2mm beneath in a pain-free, non-invasive manner. Its patented software then creates real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey.

Read More

MEDICAL DEVICES

BD Acquires Scanwell Health, Inc. to Expand and Scale Digital At-Home Testing

BD | December 22, 2021

BD (Becton, Dickinson and Company), a leading global medical technology company, today announced it has completed the acquisition of privately held Scanwell Health Inc., a leader in smartphone-enabled at-home medical tests.BD collaborated with Scanwell to develop the app used with the recently launched BD Veritor™ At-Home COVID-19 Test, the first at-home COVID-19 test that uniquely uses a smartphone camera and app to capture and interpret results, eliminating the human subjectivity in other visually read at-home antigen tests. Scanwell will become the foundational digital platform upon which BD plans to develop at-home diagnostic tests for a range of infectious diseases including COVID-19/influenza A+B, group A strep and additional menu for detecting infections and managing chronic disease. "The COVID-19 pandemic has accelerated the shift to new care settings, and BD is ready to deliver a smart, connected at-home diagnostic ecosystem to support traditional and telehealth providers and consumers. This acquisition will enable us to expand and scale our digital capabilities in-house to speed time to market for transformative at-home solutions now and in the future." Dave Hickey, president of Life Sciences for BD The Scanwell app is a key differentiator in the market for at-home COVID-19 testing. To date, no other company uses the phone's camera to capture the image of the test that is then analyzed and interpreted by the app. Other COVID-19 home tests use smartphones as part of their process, but BD Veritor™ At-Home COVID-19 Test is the first and only test to use the smartphone as the analyzer to digitally interpret the test results and provide a definitive POSITIVE or NEGATIVE digital display of testing results. The app also has the capabilities to securely store and report test results to organizations, including businesses, public health authorities and schools. The results of tests are stored in the app and can be referenced and displayed at any time by simply logging into the app. Terms of the transaction were not disclosed. The transaction is expected to be immaterial to BD's fiscal 2022 financial results. Scanwell financial results will be reported under the Integrated Diagnostic Solutions business within the Life Sciences segment. About the BD Veritor™ At-Home COVID-19 Test The BD Veritor™ At-Home COVID-19 Test has not been FDA cleared or approved; but has been authorized by FDA under Emergency Use Authorization (EUA). This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

Read More

Spotlight

Simplee commissioned Forrester Consulting to conduct a Total Economic Impact TEI study and examine the potential return on investment ROI enterprises may realize by deploying Simplee’s platform for patient financial care. The purpose of this study is to provide readers with a framework to evaluate the potential financial impact of Simplee on their organizations.

Resources